FDA — authorised 5 April 2013
- Application: NDA203168
- Marketing authorisation holder: BAUSCH AND LOMB
- Local brand name: PROLENSA
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
🇺🇸 Dexycu intracameral dexamethasone in United States
FDA authorised Dexycu intracameral dexamethasone on 5 April 2013
Marketing authorisation
Other Ophthalmology approved in United States
Frequently asked questions
Is Dexycu intracameral dexamethasone approved in United States?
Yes. FDA authorised it on 5 April 2013.
Who is the marketing authorisation holder for Dexycu intracameral dexamethasone in United States?
BAUSCH AND LOMB holds the US marketing authorisation.